Long‐term outcomes of primary cardiac malignant tumors: Difference between African American and Caucasian population

Bui, Quoc; Ngo, Tam N.M.; Mazur, J; Pham, Vy; Palmer, Cassady; Truong, Binh Quang; Chung, Eugene S.; Vuong, Huy Gia; Truong, Vien T.

doi:10.1002/cam4.4385

Cited by 5 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In multivariate analysis, older age, earlier era diagnosis, sarcoma, and non-surgical treatment options were associated with poor survival. Our results are similar to those reported by Bui et al ( 29 ) and Yin et al ( 30 ). Bui et al ( 29 ) demonstrated survival improvement in patients diagnosed in the recent era compared to old era (The 1-year survival rate: 13.3% (1975–1998), 40.9% (1999–2004), 50% (2005–2010), and 59.7% (2011–2016), p -value = 0.0064), however, Yin et al ( 30 ) study did not show this survival advantages although there was an obvious trend ( P = 0.13).…”

Section: Discussionsupporting

confidence: 93%

“…The South region had a higher proportion of black patients as compared to Northeast. There is no evidence that racial difference affects the long-term survival among patients with cardiac tumors ( 29 , 30 ). In previous reports about impact of geographic location on cancer survival, the authors surmised that the survival advantages of one geographic region area over others was mainly attributed to socioeconomic status, income and education levels, healthcare facilities inequalities, and less access to medical care (in rural vs. urban areas) rather than racial differences ( 12 – 17 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Geographic variation in malignant cardiac tumors and their outcomes: SEER database analysis

et al. 2023

View full text Add to dashboard Cite

IntroductionPrimary malignant cardiac tumors (PMCTs) are rare. Geographical distribution has been demonstrated to affect cancer outcomes, making the reduction of geographical inequalities a major priority for cancer control agencies. Geographic survival disparities have not been reported previously for PMCT and the aim of this study is to compare the prevalence and the long-term survival rate with respect to the geographic location of PMCTs using the Surveillance, Epidemiology, and End Results (SEER) research plus data 17 registries between 2000 and 2019.MethodsThe SEER database was queried to identify geographic variation among PMCTs. We classified the included states into 4 geographical regions (Midwest, Northeast, South and West regions) based on the U.S. Census Bureau-designated regions and divisions. Different demographic and clinical variables were analyzed and compared between the four groups. Kaplan Meier curves and Cox regression were used for survival assessment.ResultsA total of 563 patients were included in our analysis. The median age was 53 years (inter-quartile range (IQR): 38 - 68 years) and included 26, 90, 101, and 346 patients from the Midwest, Northeast, South, and West regions respectively. Sarcoma represented 65.6% of the cases, followed by hematological tumors (26.2%), while mesothelioma accounted for 2.1%. Treatment analysis showed no significant differences between different regions. Median overall survival was 11, 21, 13, and 11 months for Midwest, Northeast, South and West regions respectively and 5-year overall survival was 22.2%, 25.4%, 14.9%, and 17.6% respectively. On multivariate Cox regression, significant independent predictors of late overall mortality among the entire cohort included age (Hazard Ratio [HR] 1.028), year of diagnosis (HR 0.967), sarcoma (HR 3.36), surgery (HR 0.63) and chemotherapy (HR 0.56).ConclusionPrimary malignant cardiac tumors are rare and associated with poor prognosis. Sarcoma is the most common pathological type. Younger age, recent era diagnosis, surgical resection, and chemotherapy were the independent predictors of better survival. While univariate analysis revealed that patients in the South areas had a worse survival trend compared to other areas, geographic disparity in survival was nullified in multivariate analysis.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Geographic variation in malignant cardiac tumors and their outcomes: SEER database analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…manner (14). Bui et al and Sheth et al found no differences in overall survival amongst White, Black, and "Other" races in their analyses (15,16). A limitation of these studies is the representation of various races and tumor histologies as a single category causing an unclear understanding of distinct behaviors in each of the diverse groups included in this disease (17)(18)(19)(20).…”

Section: Discussionmentioning

confidence: 89%

“…Six hundred and eighty-four (95%) patients had followup data available for a median cancer-specific survival time of 14 (13)(14)(15) months. Cancer-specific death rates were 44% for Whites, 32% for Blacks, and 33% for Asians/Pacific Islanders (p = 0.040).…”

Section: Cancer-specific Survival Across Racesmentioning

confidence: 99%

Racial and ethnic characteristics and cancer-specific survival in Primary Malignant Cardiac Tumors

Aloysius

Shrivastava

Rojulpote

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThere is limited insight into the epidemiological characteristics and effect of race and ethnicity on Primary Malignant Cardiac Tumors (PMCTs).ObjectivesComparison of clinical characteristics and cancer-specific survival outcomes of major races in the United States from the Surveillance, Epidemiology and End-Result (SEER) registry.MethodsICD-O-3 codes were used to identify PMCTs for the years 1975 to 2015. Three major races were identified—“White”, “Black”, and “Asian/Pacific Islander”. Cancer-specific survival outcomes were compared using Kaplan-Meier analysis across and amongst races, based on tumor histology. A subgroup analysis of cancer-specific survival was performed between “Hispanics” and “non-Hispanics.”ResultsSeven hundred and twenty patients were identified−47% females and 79% White, mean age at diagnosis (47 ± 20 years). Black patients were significantly younger (39 ± 18 years) and presented more commonly with angiosarcomas (53%). Non-angiogenic sarcomas and lymphomas were the most common tumors in the White (38%) and Asian/Pacific Islander (34%) cohorts. For a median follow-up period of 50 (IQR3-86) months, cancer-specific survival (mean ± SD, in months) was worse in Blacks (9 ± 3) as compared to Whites (15 ± 1) and Asian/Pacific Islander (14 ± 1) (p-value; Black vs. White <0.001; Black vs. Asian/Pacific Islanders = 0.017, White vs. Asian/Pacific Islanders = 0.3). Subgroup analysis with 116 (16%) Hispanics (40% females; mean age of 40 ± 20 years) showed a longer mean cancer-specific survival of 16.9 ± 2.4 months as compared to 13.6 ± 1.1 months in non-Hispanics (p = 0.011).ConclusionBlack and non-Hispanic patients have poorer cancer-specific survival in PMCTs.

show abstract

“…Although PMCTs can present at any age, this lethal tumor is often diagnosed in the fifth decade of life, and has a poor prognosis compared to other cardiac tumors [ 3 , 10 , 12 , 13 ]. For instance, the 5-year survival of PMCTs is reported to be less than 18% across all histopathological types, with a median survival of 12 months [ 3 , 11 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Reduced Risk of All-Cause, Cancer-, and Cardiovascular Disease-Related Mortality among Patients with Primary Malignant Cardiac Tumors Receiving Chemotherapy in the United States

Appiah,

Goodart,

Kothari

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Primary malignant cardiac tumors (PMCTs) are rare but lethal neoplasms. There are limited evidence-based treatment guidelines for PMCTs. We evaluated the relation of chemotherapy with mortality outcomes in patients with PMCTs in the United States. Data were from patients aged ≥ 20 years from the Surveillance, Epidemiology, and End Results program who were diagnosed with PMCTs from 2000 to 2020. Cox regression, competing risk, and propensity score analyses were performed to estimate hazard ratios (HR) and confidence intervals (CI). About 53% of the 563 patients with PMCTs received chemotherapy as the first course of treatment. During a mean follow-up of 24.7 months (median: 10), 458 deaths occurred with 81.7% and 9.4% due to cancer and cardiovascular disease (CVD), respectively. In models adjusted for sociodemographic and clinico-pathophysiological factors including histology, receipt of chemotherapy was associated with low risk for all-cause (HR: 0.56, 95%CI: 0.45–0.69), cancer (HR: 0.63, 95%CI: 0.50–0.80) and CVD mortality (HR: 0.27, 95%CI: 0.12–0.58). Patients who had both chemotherapy and surgery had the lowest risk for all-cause and cancer mortality. This study suggests that the subpopulations of patients with PMCTs who receive chemotherapy may have better prognosis than those who do not receive this therapy regardless of histology.

show abstract

Long‐term outcomes of primary cardiac malignant tumors: Difference between African American and Caucasian population

Cited by 5 publications

References 18 publications

Geographic variation in malignant cardiac tumors and their outcomes: SEER database analysis

Geographic variation in malignant cardiac tumors and their outcomes: SEER database analysis

Racial and ethnic characteristics and cancer-specific survival in Primary Malignant Cardiac Tumors

Reduced Risk of All-Cause, Cancer-, and Cardiovascular Disease-Related Mortality among Patients with Primary Malignant Cardiac Tumors Receiving Chemotherapy in the United States

Contact Info

Product

Resources

About